Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)

RegulatorypositiveCosentyxPositive

AI Analysis

Summary

Novartis received a positive Committee for Medicinal Products for Human Use (CHMP) opinion for Cosentyx in polymyalgia rheumatica, advancing the drug toward European regulatory approval.

Outcome Details

Positive CHMP opinion received

Importance:7/10

Sentiment:

0.80

CHMPregulatory approvalrheumatologyEurope

Related Companies

$NVS

Read the original article

Published by yahoo_finance on September 18, 2026 2:51 PM

Read Original